Læknablaðið - 15.09.2005, Qupperneq 24

FRÆÐIGREINAR / BLÓÐÞYNNINGARMEÐFERÐ
verið sýnt fram á, það er að hjúkrunarfræðingar
geta allt eins vel stýrt blóðþynningarmeðferð og
læknar (15). A árinu 2003 voru enn sex sjúklingar
undir ófullnægjandi eftirliti (10%) en það ætti að
vera mögulegt að minnka það hlutfall enn frekar,
til dæmis með tölvukerfi sem gerir viðvart ef sjúk-
lingar mæta ekki í eftirlit á réttum tíma.
Þakkir
Höfundur vill þakka Sigurði Halldórssyni lækni,
starfsfólki Heilbrigðisstofnunar Pingeyinga og
Þorláki Axel Jónssyni kennara fyrir þarfar ábend-
ingar og aðstoð. Heilbrigðisstofnun Þingeyinga
fékk gæðastyrk til verkefnisins frá Heilbrigðis- og
tryggingamálaráðuneytinu.
Heimlldir
1. Heilbrigöis- og tryggingamálaráðuneytið. Notkun lyfja á ís-
landi 1994-2003. Reykjavík, 2004. http://heilbrigdisraduneyti.is/
media/Lyfjamal_-_skyrslur/Lyfjanotkun_a_Islandi_l994-2003.
pdf
2. Guðmundsdóttir I, Helgason KO, Sigurðsson EL, Arnar DO.
Notkun blóðþynningarlyfja hjá sjúklingum með gáttatif á
Islandi. Læknablaðið 2002; 88:299-303.
3. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, et
al. Managingoral anticoagulant therapy. Chest 2001; 119/Suppl
1: 22S-38S.
4. Gadisseur APA, Breukink-Engbers WGM, van der Meer FJM,
van den Besselaar AMH, Sturk A, Rosendaal FR. Comparison
of the quality of oral anticoagulant therapy through patient
self-management and management by specialized anticoagula-
tion clinics in the Netherlands. Arch Int Med 2003; 163: 2639-
46.
5. Holm T, Deutch S, Lassen JF, Jastrup B, Husted SE, Heicken-
dorff L. Prospective evaluation of the quality of oral antico-
agulation management in an outpatient clinic and in general
practices. Thromb Res 2002; 15:103-8.
6. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton
E, et al. Comparing the quality of oral anticoagulant manage-
ment by anticoagulation clinics and by family physicians: a
randomized controlled trial. CMAJ 2003; 169:293-8.
7. Walton RT, Harvey E, Dovey S, Freemantle N. Computerized
advice on drug dosage to improve prescribing practice
(Cochrane Review). í: The Cochrane Library, Issue 4, 2004.
Chichester, UK: John Wiley & Sons, Ltd.
8. Holm T, Lassen JF, Husted SE, Heickendorff L. The quality
of routine oral anticoagulant therapy in a large geographical
area. A survey of 310,300 inhabitants. Dan Med Bull 2002; 49:
252-5.
9. Nilsson GH, Björnholt I. Occurrence and quality of anticoagu-
lant treatment of chronic atrial fíbrillation in primary health
care in Sweden: a retrospective study on electronic patient
records. BMC Clin Pharmacol 2004; 4:1-6.
10. Lidstone V, Janes S, Stross P. INR: Intervals of measurement
can safely extend to 14 weeks. Clin Lab Haem 2000; 22:291-3.
11. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A
method to determine the optimal intensity of oral anticoagu-
lant therapy. Thromb Haemostas 1993; 69: 236-9.
12. Hutten BA, Prins MH, Redekop WK, Tijssen JG, Keisterkamp
SH, Buller HR. Comparison of three methods to assess thera-
peutic quality control of treatment with vitamin K antagonists.
Thromb Haemost 1999; 82:1260-3.
13. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer
FJM, Vandenbroucke JP, Briét E. Optimal anticoagulant
therapy in patients with mechanical heart valves. N Eng J Med
1995; 333:11-7.
14. Haraldsson M, Önundarson PT, Guðmundsdóttir BR, Einars-
dóttir KÁ, Kristinsson Á, Pálsson K, et al. Framskyggn rann-
sókn á blóðþynningarmeðferð á Landspítalanum. Læknablaðið
1997; 84: 32-40.
15. Taylor FC, Gray A, Cohen H, Gaminara L, Ramsay M, Miller
D. Costs and effectiveness of a nurse specialist anticoagulant
service. J Clin Pathol 1997; 50: 823-8.
660 Læknablaðið 2005/91